Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

被引：2

作者：

Harbeck, N. ^{[1
]}

Vazquez, R. Villanueva ^{[2
]}

Tripathy, D. ^{[3
]}

Lu, Y. ^{[4
]}

De Laurentiis, M. ^{[5
]}

Kuemmel, S. ^{[6
]}

Taylor, D. ^{[7
]}

Bardia, A. ^{[8
]}

Hurvitz, S. ^{[9
]}

Chow, L. ^{[10
]}

Im, S. ^{[11
]}

Franke, F. ^{[12
]}

Hughes, G. ^{[13
]}

Miller, M. ^{[13
]}

Kong, O. ^{[13
]}

Chandiwana, D. ^{[13
]}

Colleoni, M. ^{[14
]}

机构：

[1] Univ Munich LMU, Dept OB & GYN, Breast Ctr, Munich, Germany

[2] Hosp St Joan Despi Moises Broggi, Inst Catala Oncol, Barcelona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[6] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[7] CHU UCL Namur Site St Elisabeth, Namur, Belgium

[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[9] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[10] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China

[11] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea

[12] Hosp Caridade Ijui, CACON, Ijui, Brazil

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Ist Europeo Oncol, Div Med Senol, Milan, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷

关键词：

D O I：

10.1016/S0959-8049(18)30260-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1LBA

引用

页码：S3 / S3

页数：1

共 50 条

[21] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
Julie, Dejan
Campone, Mario
Munster, Pamela
Ismail-Khan, Roohi
Estevez, Laura Garcia
Chavez-MacGregor, Mariana
Frassoldati, Antonio
Hui, Rina
Mayer, Ingrid A.
Cortes, Javier
Goncalves, Anthony
De Boer, Richard H.
Dirix, Luc
Tolaney, Sara M.
Lee, Soo Chin
Maur, Michela
Wang, Yingbo
Su, Faye
Dobson, Jason R.
Germa, Caroline
Hewes, Becker
Bardia, Aditya
CANCER RESEARCH, 2017, 77
[22] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
Delevry, D.
Le, Q. A.
VALUE IN HEALTH, 2020, 23 : S32 - S33
[23] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Burris, Howard A., III
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
[24] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Neven, Patrick
Rugo, Hope S.
Tolaney, Sara M.
Iwata, Hiroji
Toi, Masakazu
Goetz, Matthew P.
Kaufman, Peter A.
Lu, Yi
Haddad, Nadine
Hurt, Karla C.
Sledge, George W., Jr.
BREAST CANCER RESEARCH, 2021, 23 (01)
[25] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Patrick Neven
Hope S. Rugo
Sara M. Tolaney
Hiroji Iwata
Masakazu Toi
Matthew P. Goetz
Peter A. Kaufman
Yi Lu
Nadine Haddad
Karla C. Hurt
George W. Sledge
Breast Cancer Research, 23
[26] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
CANCER RESEARCH, 2021, 81 (04)
[27] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Campone, Mario
De Laurentiis, Michelino
Zamagni, Claudio
Kudryavcev, Igor
Agterof, Mariette
Brown-Glaberman, Ursa
Palacova, Marketa
Chatterjee, Sanjoy
Menon-Singh, Lakshmi
Wu, Jiwen
Zhou, Katie
Martin, Miguel
CANCER RESEARCH, 2021, 81 (04)
[28] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
Hortobagyi, Gabriel N.
Paluch-Shimon, Shani
Petrakova, Katarina
Villanueva, Cristian
Chan, Arlene
Nusch, Arnd
Yap, Yoon Sim
Hart, Lowell
Favret, Anne
Marschner, Norbert
Sonke, Gabe S.
Ohnstad, Hege Oma
Arteaga, Carlos
Su, Fei
He, Wei
Miller, Michelle Kristine
Stemmer, Salomon M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
Janni, Wolfgang
Burris, Howard A.
Blackwell, Kimberly L.
Hart, Lowell L.
Chan, Arlene
Nusch, Arnd
Burdaeva, Olga Nikolaevna
Alba, Emilio
Yardley, Denise A.
Bachelot, Thomas Denis
Gil, Miguel J. Gil
Richards, Donald A.
Sparano, Joseph A.
Kattan, Joseph Gergi
Bourgeois, Hugues Pierre
El Karak, Fadi Rafic
Ramaswamy, Bhuvaneswari
Sutradhar, Santosh C.
Miller, Michelle Kristine
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
Verma, Sunil
O'Shaughnessy, Joyce
Burris, Howard A.
Campone, Mario
Alba, Emilio
Chandiwana, David
Dalal, Anand A.
Sutradhar, Santosh
Monaco, Mauricio
Janni, Wolfgang
BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (03) : 535 - 545

← 1 2 3 4 5 →